Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness

被引:21
作者
Augustin, Herbert [1 ]
Mayrhofer, Katrin [1 ]
Pummer, Karl [1 ]
Mannweiler, Sebastian [2 ]
机构
[1] Med Univ Graz, Dept Urol, A-8036 Graz, Austria
[2] Med Univ Graz, Inst Pathol, A-8036 Graz, Austria
关键词
cancer volume; Gleason score; PCA3; prognostic marker; radical prostatectomy; MOLECULAR URINE ASSAY; SCORE; MEN; VOLUME;
D O I
10.1002/pros.22558
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Data supporting prostate cancer gene 3 (PCA3) as prognostic marker are still inconsistent. With special emphasis to Gleason pattern specific tumor volumes (TVs) the relationships between PCA3 score and different characteristics of tumor aggressiveness were meticulously analyzed. METHODS In 127 patients treated with radical prostatectomy for clinically localized prostate cancer, urinary PCA3 score was quantified using Progensa (TM) PCA3 assay. Total TV and Gleason patterns' specific tumor volumes (GPTV) were assessed by computer-assisted planimetry. Spearman's rank correlations coefficients (r) were calculated to assess relationships between PCA3 and TV as well as GPTV. Regression analyses were performed to estimate the relationship between PCA3 and TV as well as non-organ confined disease. RESULTS Mean patients' age was 60.8 years. Patients showed a mean PSA level of 8.1?ng/ml and a mean PCA3 score of 68.5. PCA3 was not significantly correlated with TV (r?=?0.131, P?=?0.142). Stratified by Gleason score groups =6, 7, and =8, PCA3 showed no significant correlations with TV. In a subgroup analysis of 50 patients with different primary and secondary Gleason patterns there was neither a correlation with the primary GPTV (r?=?0.071, P?=?0.626) nor with the secondary GPTV (r?=?0.052, P?=?0.722). The PCA3 score was neither an independent predictor for TV nor for non-organ confined disease. CONCLUSIONS The PCA3 score did not show any significant correlation with TV, primary or secondary GPTV. Moreover, the PCA3 score was not an independent predictor for TV or for non-organ confined disease. Thus, the PCA3 score had no impact for the prediction of aggressive prostate cancers. Prostate 73: 203210, 2013. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:203 / 210
页数:8
相关论文
共 19 条
  • [1] [Anonymous], 2009, UICC INT UNION CANC
  • [2] Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer
    Auprich, Marco
    Bjartell, Anders
    Chun, Felix K. -H.
    de la Taille, Alexandre
    Freedland, Stephen J.
    Haese, Alexander
    Schalken, Jack
    Stenzl, Arnulf
    Tombal, Bertrand
    van der Poel, Henk
    [J]. EUROPEAN UROLOGY, 2011, 60 (05) : 1045 - 1054
  • [3] Critical Assessment of Preoperative Urinary Prostate Cancer Antigen 3 on the Accuracy of Prostate Cancer Staging
    Auprich, Marco
    Chun, Felix K. -H.
    Ward, John F.
    Pummer, Karl
    Babaian, Richard
    Augustin, Herbert
    Luger, Ferdinand
    Gutschi, Stefan
    Budaeus, Lars
    Fisch, Margit
    Huland, Hartwig
    Graefen, Markus
    Haese, Alexander
    [J]. EUROPEAN UROLOGY, 2011, 59 (01) : 96 - 105
  • [4] Bussemakers MJG, 1999, CANCER RES, V59, P5975
  • [5] Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context
    Draisma, Gerrit
    Etzioni, Ruth
    Tsodikov, Alex
    Mariotto, Angela
    Wever, Elisabeth
    Gulati, Roman
    Feuer, Eric
    de Koning, Harry
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (06): : 374 - 383
  • [6] The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy
    Durand, Xavier
    Xylinas, Evanguelos
    Radulescu, Camelia
    Haus-Cheymol, Rachel
    Moutereau, Stephane
    Ploussard, Gillaume
    Forgues, Aurelien
    Robert, Gregoire
    Vacherot, Francis
    Loric, Sylvain
    Allory, Yves
    Ruffion, Alain
    de la Taille, Alexandre
    [J]. BJU INTERNATIONAL, 2012, 110 (01) : 43 - 49
  • [7] The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
    Epstein, JI
    Allsbrook, WC
    Amin, MB
    Egevad, LL
    Bastacky, S
    Beltrán, AL
    Berner, A
    Billis, A
    Boccon-Gibod, L
    Cheng, L
    Civantos, F
    Cohen, C
    Cohen, MB
    Datta, M
    Davis, C
    Delahunt, B
    Delprado, W
    Eble, JN
    Foster, CS
    Furusato, M
    Gaudin, PB
    Grignon, DJ
    Humphrey, PA
    Iczkowski, KA
    Jones, EC
    Lucia, S
    McCue, PA
    Nazeer, T
    Oliva, E
    Pan, CC
    Pizov, G
    Reuter, V
    Samaratunga, H
    Sebo, T
    Sesterhenn, I
    Shevchuk, M
    Srigley, JR
    Suzigan, S
    Takahashi, H
    Tamboli, P
    Tan, PH
    Têtu, B
    Tickoo, S
    Tomaszewski, JE
    Troncoso, P
    Tsuzuki, T
    True, LD
    van der Kwast, T
    Wheeler, TM
    Wojno, KJ
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) : 1228 - 1242
  • [8] Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy
    Haese, Alexander
    de la Taille, Alexandre
    van Poppel, Hendrik
    Marberger, Michael
    Stenzl, Arnulf
    Mulders, Peter F. A.
    Huland, Hartwig
    Abbou, Clement-Claude
    Remzi, Mesut
    Tinzl, Martina
    Feyerabend, Susan
    Stillebroer, Alexander B.
    van Gils, Martijn P. M. Q.
    Schalken, Jack A.
    [J]. EUROPEAN UROLOGY, 2008, 54 (05) : 1081 - 1088
  • [9] Predictive Value of PCA3 in Urinary Sediments in Determining Clinico-Pathological Characteristics of Prostate Cancer
    Hessels, Daphne
    van Gils, Martijn P. M. Q.
    van Hooij, Onno
    Jannink, Sander A.
    Witjes, J. Alfred
    Verhaegh, Gerald W.
    Schalken, Jack A.
    [J]. PROSTATE, 2010, 70 (01) : 10 - 16
  • [10] Howlader N., SEER Cancer Statistics Review, 19752018